ENLV, IL0011319527

Enlivex stock trades at 1.14 euros on Lang & Schwarz

Published on 11/12/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Enlivex stock is advancing Allocetra for osteoarthritis and operates a Rain-focused treasury strategy. The company trades under ENLV on Nasdaq.

Enlivex business and trading context

  • Enlivex is developing Allocetra as a therapy for osteoarthritis.
  • Its second business line centers on a treasury strategy focused on the Rain prediction markets protocol.
ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex stock traded at 1.14 euros on Lang & Schwarz at 1:15:52 p.m. CET on Thursday, November 12, 2026.

Two business lines shape Enlivex

Enlivex is developing Allocetra, a therapy designed for immune rebalancing and late-stage clinical development in osteoarthritis. The company also manages a treasury strategy focused on the Rain prediction markets protocol, according to its investor information.

The investor page identifies the company as listed on Nasdaq under the ticker ENLV. For investors, the clinical pipeline and the digital-asset treasury strategy represent separate parts of the company's positioning.

Enlivex trading profile

  • Company: Enlivex
  • ISIN: IL0011319527
  • Ticker: ENLV
  • Listing: Nasdaq
  • Lang & Schwarz price: 1.14 euros
  • Quote time: Thursday, November 12, 2026, 1:15:52 p.m. CET

The broader US market is followed through the S&P 500.

More news and analyses on Enlivex stock.

Disclaimer...
en | IL0011319527 | ENLV | boerse | 70497829 | bgmi